Photo: streetinsider.com
Biogen Showcases Breakthrough Gene Data on Felzartamab at Kidney Week 2025
Biogen presents groundbreaking gene expression data on felzartamab for IgA nephropathy at Kidney Week 2025, showcasing its potential impact on nephrology treatments.
- Biogen will present longitudinal gene expression data from its Phase 2 IGNAZ study at the American Society of Nephrologys Kidney Week 2025 in Houston, Texas, from November 5-9.
- The presentation will feature RNAseq data linking changes in gene expression to the mechanism of action of felzartamab, an investigational treatment for IgA nephropathy.
- Felzartamabs clinical development aims to address significant unmet needs in patients with IgA nephropathy, highlighting Biogens commitment to advancing nephrology research.
Por Qué Es Relevante
This presentation underscores Biogens innovative approach in nephrology, particularly in tackling IgA nephropathy, a condition with limited treatment options. The findings could pave the way for new therapies and improve patient outcomes.